Jurgen Fingerle
Overview
Explore the profile of Jurgen Fingerle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
735
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aebi J, Atz K, Ametamey S, Benz J, Blaising J, Butini S, et al.
Chimia (Aarau)
. 2024 Sep;
78(7-8):499-512.
PMID: 39221845
The endocannabinoid system (ECS) is a critical regulatory network composed of endogenous cannabinoids (eCBs), their synthesizing and degrading enzymes, and associated receptors. It is integral to maintaining homeostasis and orchestrating...
2.
Chicca A, Batora D, Ullmer C, Caruso A, Gruner S, Fingerle J, et al.
ACS Pharmacol Transl Sci
. 2024 Aug;
7(8):2424-2438.
PMID: 39144568
The cannabinoid CB2 receptor (CB2R) is a potential therapeutic target for distinct forms of tissue injury and inflammatory diseases. To thoroughly investigate the role of CB2R in pathophysiological conditions and...
3.
Grether U, Foxton R, Gruener S, Korn C, Kimbara A, Osterwald A, et al.
Front Pharmacol
. 2024 Jul;
15:1426446.
PMID: 39070793
Introduction: Preclinical studies suggest that cannabinoid receptor type 2 (CB2R) activation has a therapeutic effect in animal models on chronic inflammation and vascular permeability, which are key pathological features of...
4.
Chicca A, Batora D, Ullmer C, Caruso A, Fingerle J, Hartung T, et al.
bioRxiv
. 2024 Jun;
PMID: 38903103
The cannabinoid CB2 receptor (CB2R) is a potential therapeutic target for distinct forms of tissue injury and inflammatory diseases. To thoroughly investigate the role of CB2R in pathophysiological conditions and...
5.
Gazzi T, Brennecke B, Atz K, Korn C, Sykes D, Forn-Cuni G, et al.
Chem Sci
. 2022 Jun;
13(19):5539-5545.
PMID: 35694350
Despite its essential role in the (patho)physiology of several diseases, CBR tissue expression profiles and signaling mechanisms are not yet fully understood. We report the development of a highly potent,...
6.
Brennecke B, Gazzi T, Atz K, Fingerle J, Kuner P, Schindler T, et al.
Pharm Pat Anal
. 2021 Jun;
10(3):111-163.
PMID: 34111979
The G-protein-coupled cannabinoid receptor type 2 (CBR) is a key element of the endocannabinoid (EC) system. EC/CBR signaling has significant therapeutic potential in major pathologies affecting humans such as allergies,...
7.
Sarott R, Westphal M, Pfaff P, Korn C, Sykes D, Gazzi T, et al.
J Am Chem Soc
. 2020 Sep;
142(40):16953-16964.
PMID: 32902974
Pharmacological modulation of cannabinoid type 2 receptor (CBR) holds promise for the treatment of numerous conditions, including inflammatory diseases, autoimmune disorders, pain, and cancer. Despite the significance of this receptor,...
8.
Haider A, Kretz J, Gobbi L, Ahmed H, Atz K, Burkler M, et al.
J Med Chem
. 2019 Nov;
62(24):11165-11181.
PMID: 31751140
The cannabinoid type 2 (CB2) receptor has emerged as a valuable target for therapy and imaging of immune-mediated pathologies. With the aim to find a suitable radiofluorinated analogue of the...
9.
Porter R, Szczesniak A, Toguri J, Gebremeskel S, Johnston B, Lehmann C, et al.
Molecules
. 2019 Sep;
24(18).
PMID: 31540271
(1) Background: The cannabinoid 2 receptor (CBR) is a promising anti-inflammatory drug target and development of selective CBR ligands may be useful for treating sight-threatening ocular inflammation. (2) Methods: This...
10.
Storti F, Klee K, Todorova V, Steiner R, Othman A, van der Velde-Visser S, et al.
Elife
. 2019 Mar;
8.
PMID: 30864945
Age-related macular degeneration (AMD) is a progressive disease of the retinal pigment epithelium (RPE) and the retina leading to loss of central vision. Polymorphisms in genes involved in lipid metabolism,...